Vyndaqel: Uses, Dosage & Side Effects
A transthyretin (TTR) stabilizer for the treatment of transthyretin amyloidosis with polyneuropathy (ATTR-PN) in adults
Vyndaqel (tafamidis meglumine) is a prescription medication used for the treatment of transthyretin amyloidosis with polyneuropathy (ATTR-PN) in adults with symptomatic disease. Tafamidis is a selective transthyretin stabilizer that binds to the thyroxine-binding sites on the TTR tetramer, preventing its dissociation into monomers that can misfold and aggregate into amyloid fibrils. By stabilizing the protein in its native tetrameric form, Vyndaqel slows the progression of neurological impairment in patients with this rare and debilitating condition. Approved by the EMA under exceptional circumstances due to the rarity of the disease, Vyndaqel is taken as a single 20 mg soft capsule once daily and has demonstrated efficacy in delaying peripheral neurological progression in clinical trials.
Quick Facts: Vyndaqel
Key Takeaways
- Vyndaqel (tafamidis) is the first approved disease-modifying treatment specifically designed to stabilize transthyretin (TTR) and delay the progression of transthyretin amyloidosis with polyneuropathy (ATTR-PN) in adults.
- The medication works by binding to the thyroxine-binding sites on the TTR tetramer, preventing the rate-limiting step of tetramer dissociation that leads to amyloid fibril formation and tissue deposition.
- The recommended dose is one 20 mg soft capsule taken orally once daily, with or without food, and treatment should be continued long-term under medical supervision.
- Common side effects include diarrhea, urinary tract infections, and abdominal pain; the drug has a generally favorable safety profile for a rare disease treatment.
- Women of childbearing potential must use effective contraception during treatment and for one month after stopping Vyndaqel, as the drug should not be used during pregnancy or breastfeeding.
What Is Vyndaqel and What Is It Used For?
Vyndaqel contains the active substance tafamidis (as tafamidis meglumine), a small molecule that acts as a selective stabilizer of the transthyretin (TTR) protein. TTR is a transport protein synthesized primarily in the liver that circulates in the blood as a homotetramer — a structure composed of four identical protein subunits arranged in a symmetrical complex. Under normal physiological conditions, TTR serves as a carrier for thyroxine (T4) and retinol-binding protein, playing an essential role in the transport of thyroid hormones and vitamin A throughout the body.
In patients with transthyretin amyloidosis, either due to inherited mutations in the TTR gene (hereditary ATTR, also known as ATTRv) or age-related changes in the wild-type protein (wild-type ATTR, or ATTRwt), the TTR tetramer becomes unstable and dissociates into individual monomers. These monomers then misfold into abnormal protein structures that aggregate and form insoluble amyloid fibrils. These amyloid fibrils deposit in various tissues and organs throughout the body, progressively damaging them and causing a range of debilitating symptoms depending on the primary sites of deposition.
When amyloid fibrils accumulate around peripheral nerves, the condition is known as transthyretin amyloidosis with polyneuropathy (ATTR-PN). This form of the disease typically presents with a length-dependent sensorimotor polyneuropathy, meaning that symptoms usually begin in the feet and hands and gradually progress upward. Patients may experience numbness, tingling, burning pain, loss of sensation, muscle weakness, and difficulty walking. Autonomic nervous system involvement is also common, leading to symptoms such as orthostatic hypotension (dizziness upon standing), gastrointestinal disturbances (diarrhea, constipation, nausea), urinary dysfunction, and erectile dysfunction. Without treatment, ATTR-PN is a progressive and ultimately fatal condition, with a median survival of approximately 7 to 12 years after symptom onset, depending on the specific TTR mutation involved.
Tafamidis works by binding with high selectivity to the two thyroxine-binding sites on the TTR tetramer, stabilizing the protein complex and preventing the initial and rate-limiting step in the amyloidogenic cascade — tetramer dissociation. By keeping the TTR protein in its normal, functional tetrameric form, tafamidis reduces the availability of misfolded monomers and thereby slows the formation of new amyloid fibrils. This mechanism of action has been demonstrated in vitro using acid-mediated TTR dissociation assays and confirmed in vivo through measurements of TTR stabilization in patient serum samples during clinical trials.
The pivotal clinical trial supporting the approval of Vyndaqel for ATTR-PN was the Fx-005 study, a randomized, double-blind, placebo-controlled trial conducted in 128 patients with early-stage hereditary ATTR-PN caused by the most common TTR mutation, Val30Met (V30M). Patients were randomized to receive tafamidis 20 mg once daily or placebo for 18 months. The primary efficacy endpoints were the change from baseline in the Neuropathy Impairment Score in the Lower Limbs (NIS-LL) and the Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) total score. In the intention-to-treat (ITT) analysis, the co-primary endpoints did not reach statistical significance, partly due to the high dropout rate in the placebo group. However, in the evaluable population (patients who completed all assessments), tafamidis demonstrated a statistically significant benefit over placebo in slowing NIS-LL progression, and the treatment was associated with a significantly greater rate of TTR stabilization. Subsequent long-term open-label extension studies over 5.5 years confirmed that early initiation of tafamidis treatment was associated with sustained preservation of neurological function and quality of life compared with delayed treatment.
Vyndaqel was first approved by the European Medicines Agency (EMA) in November 2011 under exceptional circumstances, reflecting the rarity of the disease and the difficulty in conducting large-scale clinical trials. The EMA reviews all available data on the medication annually to ensure the benefit-risk balance remains favorable. Vyndaqel is also approved in Japan and several other countries for the treatment of ATTR-PN. In the United States, a higher-dose formulation (tafamidis 61 mg free acid, marketed as Vyndamax, or tafamidis meglumine 80 mg, marketed as Vyndaqel) is approved specifically for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), a related condition where amyloid deposits primarily in the heart.
Transthyretin amyloidosis is a rare, progressive disease that can be inherited (hereditary ATTR, caused by mutations in the TTR gene) or acquired (wild-type ATTR, associated with aging). More than 130 different TTR mutations have been identified worldwide, with the Val30Met mutation being the most common cause of hereditary ATTR-PN. The disease is endemic in certain populations, particularly in Portugal, Sweden, Japan, and Brazil, where carrier frequencies are highest. Early diagnosis and treatment are crucial, as disease-modifying therapies like tafamidis are most effective when started in the early stages of neurological impairment.
What Should You Know Before Taking Vyndaqel?
Contraindications
The primary contraindication for Vyndaqel is hypersensitivity (allergy) to tafamidis meglumine or to any of the other ingredients in the formulation. The inactive ingredients in Vyndaqel soft capsules include gelatin, glycerin, sorbitol, mannitol, sorbitan, yellow iron oxide, titanium dioxide, purified water, macrogol 400, sorbitan monooleate, polysorbate 80, ethanol, isopropyl alcohol, polyvinyl acetate phthalate, propylene glycol, carmine, brilliant blue FCF, and ammonium hydroxide. If you have a known allergy to any of these substances, you should not take Vyndaqel.
It is important to note that Vyndaqel soft capsules contain sorbitol. Sorbitol is a source of fructose, and each capsule contains no more than 44 mg of sorbitol. Patients with rare hereditary problems of fructose intolerance should consult their physician before taking this medication, although the amount present is very small and unlikely to cause symptoms in most individuals.
Warnings and Precautions
Women of childbearing potential must use effective contraception during treatment with Vyndaqel and for at least one month after the last dose. There are no adequate data on the use of tafamidis in pregnant women. If you become pregnant during treatment, stop taking Vyndaqel and consult your doctor immediately.
Before starting Vyndaqel, discuss the following with your healthcare provider:
- Reproductive potential: Women who are able to become pregnant must use reliable contraception while taking Vyndaqel and for one month after stopping treatment. The effects of tafamidis on human pregnancy have not been studied, and the potential risk to the developing fetus is unknown. Animal studies are limited and have not provided sufficient data to rule out reproductive toxicity at clinically relevant doses.
- Liver function: Since TTR is primarily produced in the liver and tafamidis acts by stabilizing the circulating TTR protein, patients with significant liver disease should be carefully evaluated before starting treatment. Liver transplantation has historically been a treatment option for hereditary ATTR amyloidosis (as the transplanted liver produces normal TTR), and the use of tafamidis in liver transplant recipients has not been extensively studied.
- Disease monitoring: ATTR-PN is a progressive disease, and while tafamidis has been shown to delay disease progression, it does not reverse existing nerve damage. Regular neurological assessments, including nerve conduction studies and functional evaluations, are recommended to monitor disease status and treatment response. Your doctor may adjust your treatment plan based on your ongoing clinical assessments.
- Drug transporter effects: Tafamidis is an inhibitor of the breast cancer resistance protein (BCRP) transporter in vitro. This may increase the plasma concentrations of drugs that are substrates of BCRP when co-administered with tafamidis. Your doctor should be aware of all medications you are taking to assess potential interactions.
Children and Adolescents
Vyndaqel is not indicated for use in children and adolescents under 18 years of age. Transthyretin amyloidosis with polyneuropathy is an adult-onset disease, and symptoms do not typically manifest in children or adolescents even in carriers of pathogenic TTR mutations. There are no clinical data on the safety or efficacy of tafamidis in the pediatric population. Genetic testing and counseling may be offered to at-risk family members, but pharmacological treatment is not initiated until symptoms develop.
Pregnancy and Breastfeeding
Vyndaqel should not be used during pregnancy. There are no adequate and well-controlled studies of tafamidis in pregnant women. Given the mechanism of action of tafamidis and its ability to bind to TTR, which is involved in the transport of thyroxine and retinol (vitamin A), there is a theoretical concern that the drug could affect thyroid hormone and vitamin A transport to the developing fetus. Animal reproductive studies have not been adequately performed to assess the risk. As a precaution, Vyndaqel is contraindicated during pregnancy, and women of childbearing potential must use effective contraception throughout treatment and for one month after discontinuation.
It is not known whether tafamidis or its metabolites are excreted in human breast milk. A risk to the breastfed infant cannot be excluded. Therefore, Vyndaqel should not be used during breastfeeding. The decision to breastfeed or to continue treatment with Vyndaqel should be made in consultation with your healthcare provider, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
Driving and Operating Machinery
Vyndaqel is expected to have no or negligible effect on the ability to drive and use machines. No studies have specifically evaluated the effects of tafamidis on driving ability, but based on its pharmacological profile and the adverse reaction data from clinical trials, it is unlikely to impair cognitive or motor function. However, patients should be aware that ATTR-PN itself can cause symptoms such as muscle weakness, numbness, and balance difficulties that may affect the ability to drive or operate machinery safely.
How Does Vyndaqel Interact with Other Drugs?
Understanding drug interactions is essential for the safe use of any medication, and this is particularly important for patients with ATTR-PN who may be taking multiple medications to manage their various symptoms and comorbidities. Tafamidis has a specific interaction profile that differs from many other medications due to its unique mechanism of action and pharmacokinetic properties.
Tafamidis is an inhibitor of the breast cancer resistance protein (BCRP/ABCG2) drug transporter. BCRP is an efflux transporter expressed in the intestine, liver, kidneys, and blood-brain barrier that plays a role in limiting the absorption and facilitating the elimination of certain drugs. By inhibiting BCRP, tafamidis can increase the systemic exposure (blood levels) of drugs that are substrates of this transporter. This is the primary mechanism through which tafamidis may interact with other medications.
Additionally, in vitro studies have shown that tafamidis may inhibit organic anion transporter (OAT) proteins OAT1 and OAT3. These transporters are involved in the renal secretion of various drugs and their metabolites. Inhibition of OAT1 and OAT3 could potentially decrease the renal clearance of their substrates, leading to higher blood concentrations of these drugs.
The following table summarizes the known and potential drug interactions with Vyndaqel that you should discuss with your healthcare provider:
| Drug Category | Examples | Interaction Mechanism | Clinical Significance |
|---|---|---|---|
| NSAIDs | Ibuprofen, naproxen, diclofenac | Competition for TTR binding sites; BCRP substrate effects | Monitor for increased NSAID effects; inform your doctor |
| Diuretics | Furosemide, bumetanide | OAT1/OAT3 substrate; potential reduced renal clearance | Monitor kidney function and diuretic response |
| Cancer medications | Methotrexate, imatinib | BCRP and OAT substrate; may increase drug exposure | Dose adjustment may be needed; close monitoring required |
| Statins | Rosuvastatin | BCRP substrate; tafamidis may increase statin exposure | Monitor for statin-related side effects (muscle pain) |
| Antiviral agents | Oseltamivir, tenofovir, ganciclovir, adefovir, cidofovir, lamivudine, zidovudine, zalcitabine | OAT1/OAT3 substrates; potential reduced renal clearance | Monitor for increased antiviral effects and toxicity |
It is important to emphasize that the interactions listed above are based on the known pharmacological properties of tafamidis and its effects on drug transporters. Not all interactions have been confirmed in dedicated clinical drug-drug interaction studies. Your healthcare provider will assess the clinical significance of any potential interactions based on your individual medication regimen and clinical circumstances.
Always inform your doctor or pharmacist about all medicines you are taking, have recently taken, or might take, including over-the-counter medications, herbal supplements, and vitamins. This will allow your healthcare team to monitor for potential interactions and adjust your treatment plan if necessary.
What Is the Correct Dosage of Vyndaqel?
Vyndaqel is available as a 20 mg soft capsule (containing tafamidis meglumine, equivalent to 12.2 mg of tafamidis free acid). The dosage regimen is straightforward: one capsule taken by mouth once daily. This simplicity of dosing is an advantage for long-term adherence, which is critical for a disease-modifying treatment in a chronic progressive condition like ATTR-PN.
Adults
Standard Adult Dose
Dose: 20 mg (one soft capsule) once daily
Administration: Oral; swallow whole, do not crush or cut
Timing: Can be taken at any time of day, with or without food
Duration: Long-term, continuous treatment as directed by physician
The soft capsule should be swallowed whole and should not be crushed, broken, or opened. Tafamidis is designed to be absorbed through the gastrointestinal tract in its intact capsule form, and altering the capsule may affect the drug's bioavailability and therapeutic efficacy. The capsule can be taken with or without food, as food does not significantly affect the rate or extent of absorption of tafamidis.
Tafamidis reaches steady-state plasma concentrations within approximately 14 days of once-daily dosing, with a terminal elimination half-life of approximately 49 hours. This relatively long half-life supports the once-daily dosing regimen and provides consistent drug exposure throughout the 24-hour dosing interval. At steady state, tafamidis achieves plasma concentrations sufficient to stabilize the TTR tetramer throughout the dosing period.
It is important to note that Vyndaqel 20 mg soft capsules (tafamidis meglumine) are not interchangeable on a milligram-per-milligram basis with other tafamidis formulations. In some countries, a higher-strength tafamidis free acid formulation (61 mg) or a tafamidis meglumine 80 mg formulation is available, primarily for the treatment of ATTR cardiomyopathy. These different formulations have different pharmacokinetic properties and are intended for different indications. Always take the specific formulation and dose prescribed by your doctor.
Elderly Patients
No dose adjustment is required for elderly patients. ATTR-PN often affects individuals in their fifth to seventh decade of life, and the clinical trial populations included patients across a wide age range. Pharmacokinetic analyses have not identified age as a significant factor affecting tafamidis exposure. However, elderly patients should be monitored for overall health status and potential comorbidities that may influence treatment decisions.
Renal and Hepatic Impairment
The pharmacokinetics of tafamidis have not been extensively studied in patients with significant renal or hepatic impairment. Tafamidis is primarily eliminated via fecal excretion, with renal elimination playing a minor role. Patients with mild to moderate renal impairment are not expected to require dose adjustment. Patients with severe renal impairment or those requiring dialysis should be treated with caution and monitored closely, as there are limited data in this population.
Regarding hepatic impairment, since tafamidis is primarily eliminated unchanged via feces (approximately 59% of the administered dose), significant hepatic impairment may affect the production of TTR itself rather than the metabolism of tafamidis. Patients with severe hepatic impairment should be evaluated on a case-by-case basis.
Children
Vyndaqel is not indicated for use in children and adolescents under 18 years of age. ATTR-PN does not manifest clinically in the pediatric population, and no dosing recommendations can be made for this age group.
Missed Dose
If you miss a dose of Vyndaqel, take it as soon as you remember. However, if it is less than 6 hours until your next scheduled dose, skip the missed dose and take your next dose at the usual time. Do not take a double dose to make up for a missed dose. Maintaining a consistent daily dosing schedule helps ensure optimal TTR stabilization and therapeutic benefit.
If You Vomit After Taking Vyndaqel
If you vomit after taking Vyndaqel and can see the intact capsule in the vomit, you should take another dose of Vyndaqel on the same day. If you cannot see the capsule (meaning it has likely been partially or fully absorbed), do not take an additional dose. Simply continue with your regular dosing schedule the next day.
Overdose
Do not take more capsules than prescribed by your doctor. There is limited clinical experience with tafamidis overdose. In the event that you take more capsules than prescribed, contact your doctor or seek medical attention immediately. Treatment of overdose should be symptomatic and supportive. Given the high protein binding of tafamidis (greater than 99%), dialysis is unlikely to be an effective method of drug removal.
Do not stop taking Vyndaqel without first consulting your doctor. Vyndaqel works by continuously stabilizing the TTR protein. If you stop taking the medication, the TTR protein will no longer be stabilized, and the disease may progress more rapidly. Even if you feel well, it is important to continue taking Vyndaqel as prescribed to maintain TTR stabilization and slow disease progression.
What Are the Side Effects of Vyndaqel?
Vyndaqel has been evaluated in clinical trials and post-marketing surveillance, providing a comprehensive picture of its safety profile. As with all medications, side effects can occur, but not all patients will experience them. The side effects observed with Vyndaqel are generally mild to moderate in severity and are manageable with standard medical care. Understanding the potential side effects can help you recognize them early and discuss any concerns with your healthcare provider.
The side effects of Vyndaqel are classified by frequency according to international standards:
Very Common
May affect more than 1 in 10 people
- Diarrhea — loose or watery stools occurring more frequently than usual
- Urinary tract infection — symptoms may include pain or burning sensation during urination, frequent urge to urinate, or cloudy urine
- Abdominal pain — pain or discomfort in the stomach area
It is important to note that the clinical trial data for Vyndaqel in ATTR-PN were obtained from a relatively small patient population, which is typical for rare disease trials. The overall safety profile of tafamidis has been further characterized through post-marketing surveillance and long-term open-label extension studies, which have generally confirmed the favorable safety profile observed in the pivotal trial.
In the pivotal Fx-005 clinical trial, the overall incidence of adverse events was similar between the tafamidis 20 mg group and the placebo group, suggesting that many of the reported events may be related to the underlying disease process rather than the medication itself. ATTR-PN is associated with a wide range of symptoms, particularly gastrointestinal disturbances and urinary dysfunction, due to autonomic nerve involvement. Therefore, distinguishing drug-related side effects from disease-related symptoms can be challenging.
Long-term extension studies following patients for up to 5.5 years of continuous tafamidis treatment did not reveal any new or unexpected safety signals. The most frequently reported adverse events remained consistent with those observed in the initial 18-month trial, and no dose-dependent increase in adverse events was observed. The rate of serious adverse events was comparable between patients who started tafamidis early and those who switched from placebo to tafamidis during the extension phase.
Regarding cardiovascular safety, which is particularly relevant given that TTR amyloid can also deposit in the heart, the Fx-005 trial and its extension did not identify significant cardiovascular safety concerns with tafamidis 20 mg in the ATTR-PN population. However, patients with ATTR-PN should be regularly monitored for signs of cardiac involvement, as the disease can progress to include cardiomyopathy over time.
It is important to report any suspected side effects after a medicine has been authorized. This allows ongoing monitoring of the medicine's benefit-risk balance. Healthcare professionals and patients can report suspected adverse reactions to their national health authority or the European Medicines Agency (EMA) through the established pharmacovigilance reporting systems.
How Should You Store Vyndaqel?
Proper storage of medications is essential to maintain their efficacy, safety, and quality throughout their shelf life. Vyndaqel soft capsules should be stored according to the following guidelines to ensure optimal preservation of the active ingredient:
- Temperature: Store at no more than 25°C (77°F). Do not freeze the capsules. Avoid exposure to excessive heat or direct sunlight, as high temperatures can affect the integrity of the soft gelatin capsule shell and the stability of the active ingredient.
- Packaging: Keep the capsules in the original PVC/PA/aluminium blister packaging until you are ready to take them. The blister pack provides protection from moisture and light. To remove a capsule, separate one individual blister from the blister card along the perforated line, then push the capsule through the aluminium foil.
- Child safety: Keep Vyndaqel out of the sight and reach of children. The capsules are not child-resistant, and accidental ingestion by children could be harmful.
- Expiry date: Do not use Vyndaqel after the expiry date printed on the blister card and carton. The expiry date refers to the last day of the stated month. Expired medications may have reduced potency or altered chemical composition.
- Disposal: Do not dispose of medications in household waste or wastewater. Ask your pharmacist how to properly dispose of medicines you no longer use. Proper disposal helps protect the environment and prevents accidental exposure.
What Does Vyndaqel Contain?
Understanding the composition of your medication is important for identifying potential allergens and ensuring you are taking the correct product. Below is a detailed breakdown of the ingredients in Vyndaqel:
Active Ingredient
Each soft capsule contains 20 mg of micronized tafamidis meglumine, which is equivalent to 12.2 mg of tafamidis (free acid). Tafamidis meglumine is the salt form of tafamidis used in this formulation to optimize the drug's pharmaceutical properties, including solubility and absorption characteristics.
Inactive Ingredients (Excipients)
The other ingredients in Vyndaqel soft capsules are:
- Capsule shell: Gelatin (E441), glycerin (E422), sorbitol (E420), mannitol (E421), sorbitan, yellow iron oxide (E172), titanium dioxide (E171), purified water
- Capsule fill: Macrogol 400 (E1521), sorbitan monooleate (E494), polysorbate 80 (E433)
- Printing ink: Ethanol, isopropyl alcohol, polyvinyl acetate phthalate, propylene glycol (E1520), carmine (E120), brilliant blue FCF (E133), ammonium hydroxide (E527)
Appearance and Pack Sizes
Vyndaqel soft capsules are yellow, opaque, and oblong-shaped, approximately 21 mm in length, with "VYN20" printed in red ink. The capsules are supplied in PVC/PA/aluminium/PVC-aluminium perforated unit-dose blisters. Vyndaqel is available in two pack sizes: a carton containing 30 × 1 soft capsules, and a multipack containing 90 soft capsules (3 cartons of 30 × 1 soft capsules each). Not all pack sizes may be available in every country.
Frequently Asked Questions About Vyndaqel
Transthyretin amyloidosis (ATTR amyloidosis) is a rare, progressive disease caused by the misfolding of the transthyretin (TTR) protein. Normally, TTR circulates in the blood as a stable tetramer (four identical subunits) and transports thyroxine and vitamin A. In ATTR amyloidosis, the TTR tetramer becomes unstable, dissociates into monomers, misfolds, and aggregates into insoluble amyloid fibrils. These fibrils deposit in various tissues including peripheral nerves, the heart, the gastrointestinal tract, and the kidneys, causing progressive organ damage. When the nerves are primarily affected, the condition is called ATTR-PN (polyneuropathy), leading to numbness, pain, weakness, and autonomic dysfunction.
Vyndaqel begins stabilizing the TTR protein within days of starting treatment, with steady-state plasma concentrations achieved within approximately 14 days of daily dosing. However, the clinical benefits of treatment — such as slowing the progression of neuropathy — may take months to become apparent, as the medication prevents further nerve damage rather than reversing existing damage. In the pivotal clinical trial, the difference between tafamidis and placebo in neurological outcomes became evident over the 18-month study period. Long-term studies have shown sustained benefit over 5 or more years of treatment.
No, Vyndaqel does not reverse existing nerve damage. Its mechanism of action is to stabilize the TTR protein and prevent further amyloid fibril formation, thereby slowing the progression of the disease. This is why early diagnosis and initiation of treatment are crucial — starting treatment before significant nerve damage has occurred provides the best outcomes. Patients who begin treatment in the early stages of ATTR-PN have been shown to maintain better neurological function over time compared to those who start treatment later. Your doctor may recommend complementary treatments to manage existing symptoms while Vyndaqel works to slow disease progression.
Vyndaqel and Vyndamax are related but not identical products. Both contain tafamidis as the active ingredient, but they differ in formulation, strength, and indication. Vyndaqel 20 mg soft capsules (tafamidis meglumine) are approved for ATTR-PN, while Vyndamax 61 mg capsules (tafamidis free acid) and Vyndaqel 80 mg (tafamidis meglumine) are approved for transthyretin amyloid cardiomyopathy (ATTR-CM). The different formulations are not interchangeable on a milligram-per-milligram basis due to differences in bioavailability. Always take the specific formulation prescribed by your doctor.
If you stop taking Vyndaqel, the stabilization of the TTR protein will cease, and the TTR tetramer may resume dissociating into monomers that can form amyloid fibrils. This means the disease may progress more rapidly after discontinuation. In long-term clinical studies, patients who started tafamidis treatment early had significantly better neurological outcomes than those who started later, suggesting that continuous treatment provides cumulative benefit. You should never stop taking Vyndaqel without consulting your doctor, who can advise you on the risks and alternatives.
Vyndaqel was approved by the European Medicines Agency (EMA) under "exceptional circumstances" because ATTR-PN is an extremely rare disease, making it very difficult to obtain comprehensive clinical data from large-scale trials. This regulatory pathway allows medicines for rare diseases to be approved with less data than would normally be required, provided that the available evidence demonstrates a favorable benefit-risk balance. The EMA reviews all new data on Vyndaqel annually to ensure the benefits continue to outweigh the risks. Post-marketing studies and long-term extension data have supported the continued positive benefit-risk assessment.
References
- European Medicines Agency (EMA). Vyndaqel (tafamidis) – Summary of Product Characteristics. Last updated 2025. Available at: EMA EPAR.
- U.S. Food and Drug Administration (FDA). Vyndaqel/Vyndamax (tafamidis) – Prescribing Information. Revised 2024.
- Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785-792. doi:10.1212/WNL.0b013e3182661eb1
- Barroso FA, Judge DP, Ebede B, et al. Long-term safety and efficacy of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24(3):194-204. doi:10.1080/13506129.2017.1357545
- Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. Journal of Neurology. 2021;268:2109-2122.
- Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. Journal of the American College of Cardiology. 2015;66(21):2451-2466.
- Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine. 2018;379(11):1007-1016. doi:10.1056/NEJMoa1805689
- Conceicao I, Gonzalez-Duarte A, Obici L, et al. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. Journal of the Peripheral Nervous System. 2016;21(1):5-9.
- World Health Organization (WHO). Orphan Medicines – Policy and Practice. 2024.
- European Society of Cardiology (ESC). Position Statement on Diagnosis and Management of Cardiac Amyloidosis. 2023.
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Neurology, Rare Diseases, and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following WHO, EMA, and FDA guidelines
Evidence Framework
GRADE methodology – Evidence Level 1A based on systematic reviews and randomized controlled trials
Editorial Standards
No commercial funding. No pharmaceutical sponsorship. Independent peer-reviewed content.
Last medical review: | Next scheduled review: